Image: HealthlineFlu Season: FDA Approves More Effective mRNA Shot for Adults 50 and Up
• The FDA has approved mFLUSIVA, a new mRNA-based flu vaccine designed to provide enhanced protection for older adults. • Clinical trials demonstrated the vaccine is highly effective in preventing serious illness for adults aged 50 to 64, with accelerated approval granted for those 65 and older. • This approval is significant as it introduces mRNA technology to flu prevention for aging populations ahead of the 2026–2027 flu season.
healthline.com
.jpg%3Fdisable%3Dupscale%26width%3D1200%26height%3D630%26fit%3Dcrop&w=1920&q=85)

